Filing Analysis
Celularity Inc. received a written notice from Nasdaq on June 9, 2026, stating that the company failed to meet the minimum Market Value of Listed Securities (MVLS) requirement of $35 million. The company has until December 7, 2026, to regain compliance.
🚩 Red Flags
- Failure to meet minimum market capitalization requirements is often a precursor to delisting or significant dilution via capital raises.
- The company admits there is no assurance it will be successful in maintaining its listing.
📋 Key Facts
- Notice received from Nasdaq on June 9, 2026.
- Failure is based on Nasdaq Listing Rule 5550(b)(2) regarding minimum Market Value of Listed Securities (MVLS).
- The MVLS requirement is a minimum of $35 million.
- Compliance deadline is December 7, 2026 (180 calendar days).
- To regain compliance, MVLS must exceed $35 million for 10 consecutive business days.
- The company is considering alternatives, including increasing stockholders' equity to at least $2.5 million.
Celularity Inc. appointed Rick Gonzalez as Chief Commercial Officer on May 29, 2026. The filing also includes a shareholder letter from CEO Dr. Robert J. Hariri detailing the company's strategic focus on longevity and regenerative medicine.
🚩 Red Flags
- Lack of a definitive employment agreement at the time of appointment for a C-level executive.
📋 Key Facts
- Rick Gonzalez appointed as Chief Commercial Officer (CCO) effective May 29, 2026.
- Mr. Gonzalez reports directly to Chairman and CEO Robert J. Hariri, M.D., Ph.D.
- No definitive employment agreement has been entered into yet; terms will be disclosed in a future filing.
- Company issued a shareholder letter on June 3, 2026, highlighting strategic focus on cenplacel-L and the Lifebank cellular banking platform.
Celularity Inc. entered into a Settlement Agreement on May 21, 2026, with Helena Global Investment Opportunities 1 Ltd. to resolve a default on a Convertible Promissory Note and restructure obligations.
🚩 Red Flags
- The settlement is a result of a 'notice of event of default' on a debt instrument, indicating severe liquidity or payment issues.
- The company is paying cash in a structured settlement to avoid legal claims/default consequences.
- The agreement involves the surrender of preferred stock, suggesting a restructuring of the capital structure under pressure.
📋 Key Facts
- Settlement Agreement dated May 21, 2026, with Helena Global Investment Opportunities 1 Ltd.
- Helena had previously delivered a notice of event of default under a Convertible Promissory Note.
- Helena surrendered its shares of Series A Convertible Preferred Stock as part of the settlement.
- Company agrees to pay $500,000 immediately and five monthly payments of $100,000.
- Company will assign certain rights under a $2,500,000 promissory note.
- The agreement is linked to a Securities Purchase Agreement dated October 24, 2025.
Celularity Inc. disclosed a default notice from a lender due to delinquent SEC filings, alongside the departure of two senior executives and an amended $13.3 million asset sale agreement. The company failed to file its 2025 Form 10-K, triggering default provisions on a $1.97 million convertible note with an 18% interest rate.
🚩 Red Flags
- Notice of event of default on debt obligations.
- Delinquent SEC reporting (failure to file Form 10-K).
- Extremely high interest rate (18% per annum) on the Helena Note.
- Multiple high-level executive departures (CAO and a President) within one week.
- Mandatory default penalty of 115% of principal and interest.
- Multiple 8-K items (1.01, 2.03, 3.03, 5.02) indicating significant corporate distress.
📋 Key Facts
- Entered Amendment No. 1 with NexGel, Inc. for an asset sale totaling $13.3 million, including $8.3 million in upfront cash.
- Received a notice of event of default on April 17, 2026, from Helena Global Investment Opportunities 1 Ltd. regarding a $1,970,502.58 convertible note.
- The default was triggered by the company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
- The Helena Note carries an 18% annual interest rate and includes a 'Mandatory Default Amount' penalty of 115% of the outstanding balance.
- Terminated CAO John R. Haines without cause on April 9, 2026; President of Degenerative Diseases Stephen A. Brigido resigned on April 15, 2026.
- Extended the outside date for the NexGel transaction to April 30, 2026.
Celularity Inc. entered into an agreement to sell and exclusively license its commercial-stage biomaterials portfolio and certain development programs to NexGel, Inc. for up to $35 million. The transaction includes a $15 million upfront cash payment and up to $20 million in milestone payments based on future net sales.
🚩 Red Flags
- Transaction completion is contingent on the buyer (NexGel) successfully obtaining financing, introducing significant closing risk.
- The divestiture of 'commercial-stage' assets may indicate a strategic pivot or a need for immediate liquidity.
📋 Key Facts
- Agreement signed March 6, 2026, with NexGel, Inc. for the sale and exclusive licensing of the biomaterials 'Business'.
- Total potential consideration of $35.0 million, consisting of $15.0 million upfront and $20.0 million in sales-based milestones.
- The deal includes ancillary contract manufacturing and sublease agreements.
- Closing is contingent on NexGel receiving financing sufficient to cover the $15.0 million upfront payment.
Celularity Inc. announced that Joseph DosSantos, the SVP of Finance and Acting CFO, departed the company for personal reasons on February 27, 2026. John Sprague was appointed as the new Acting CFO effective the same day.
🚩 Red Flags
- Departure of the principal financial officer (Acting CFO) for 'personal reasons' can indicate underlying issues or lack of stability.
- The company continues to rely on 'Acting' leadership for the CFO role rather than a permanent appointment.
- Frequent turnover in the finance department for micro-cap companies often precedes reporting delays or restatements.
📋 Key Facts
- Joseph DosSantos resigned as SVP, Finance and Acting CFO on February 27, 2026.
- The departure was attributed to 'personal reasons'.
- John Sprague was appointed as Acting CFO on February 27, 2026.
- The filing was submitted on March 5, 2026, following the February 27 event date.